[{"address1": "221 Crescent Street", "address2": "Suite 401", "city": "Waltham", "state": "MA", "zip": "02453", "country": "United States", "phone": "617 272 4600", "fax": "617 272 4601", "website": "https://www.viridiantherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 143, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen F. Mahoney J.D., MBA", "age": 53, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 652704, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Seth  Harmon", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 552467, "exercisedValue": 0, "unexercisedValue": 405844}, {"maxAge": 1, "name": "Mr. Thomas W. Beetham J.D., MBA", "age": 54, "title": "Chief Operating Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 517000, "exercisedValue": 0, "unexercisedValue": 870322}, {"maxAge": 1, "name": "Ms. Melissa  Manno", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Casciano", "age": 47, "title": "Chief Commercial Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shan  Wu Ph.D.", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kyle B. Haraldsen", "age": 46, "title": "Chief Technical Operations Officer", "yearBorn": 1978, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Diane  Stroehmann M.S., R.A.C.", "age": 47, "title": "Senior Vice President of Regulatory Affairs", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kirk  Bertelsen", "title": "Senior VP & Head of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christian  Zdybowicz", "title": "Senior Vice President of Portfolio Strategy & Leadership", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 6, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 13.74, "open": 13.98, "dayLow": 13.285, "dayHigh": 13.99, "regularMarketPreviousClose": 13.74, "regularMarketOpen": 13.98, "regularMarketDayLow": 13.285, "regularMarketDayHigh": 13.99, "payoutRatio": 0.0, "beta": 0.855, "forwardPE": -3.2583733, "volume": 1079502, "regularMarketVolume": 1033841, "averageVolume": 940422, "averageVolume10days": 687530, "averageDailyVolume10Day": 687530, "bid": 13.56, "ask": 13.68, "bidSize": 2, "askSize": 2, "marketCap": 1111251712, "fiftyTwoWeekLow": 9.9, "fiftyTwoWeekHigh": 27.2, "priceToSalesTrailing12Months": 3679.6414, "fiftyDayAverage": 14.2065, "twoHundredDayAverage": 18.053776, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 604244992, "profitMargins": 0.0, "floatShares": 72629980, "sharesOutstanding": 81589696, "sharesShort": 11043451, "sharesShortPriorMonth": 9998425, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.1355, "heldPercentInsiders": 0.00121, "heldPercentInstitutions": 1.16537, "shortRatio": 10.63, "shortPercentOfFloat": 0.1534, "impliedSharesOutstanding": 81589696, "bookValue": 5.96, "priceToBook": 2.285235, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -208560000, "trailingEps": -3.07, "forwardEps": -4.18, "lastSplitFactor": "1:15", "lastSplitDate": 1605225600, "enterpriseToRevenue": 2000.811, "enterpriseToEbitda": -2.024, "52WeekChange": -0.12636304, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 13.62, "targetHighPrice": 61.0, "targetLowPrice": 22.0, "targetMeanPrice": 39.6875, "targetMedianPrice": 41.0, "recommendationMean": 1.52941, "recommendationKey": "buy", "numberOfAnalystOpinions": 16, "totalCash": 717584000, "totalCashPerShare": 8.806, "ebitda": -298495008, "totalDebt": 23119000, "quickRatio": 14.989, "currentRatio": 15.425, "totalRevenue": 302000, "debtToEquity": 3.442, "revenuePerShare": 0.004, "returnOnAssets": -0.3032, "returnOnEquity": -0.48479998, "grossProfits": -237952000, "freeCashflow": -136121632, "operatingCashflow": -232319008, "revenueGrowth": 0.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -1214.8889, "financialCurrency": "USD", "symbol": "VRDN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -0.87336165, "regularMarketPrice": 13.62, "corporateActions": [], "postMarketTime": 1746227719, "regularMarketTime": 1746216000, "marketState": "CLOSED", "shortName": "Viridian Therapeutics, Inc.", "longName": "Viridian Therapeutics, Inc.", "postMarketChangePercent": 4.99266, "postMarketPrice": 14.3, "postMarketChange": 0.68, "regularMarketChange": -0.119999886, "exchange": "NCM", "messageBoardId": "finmb_45015663", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1403098200000, "regularMarketDayRange": "13.285 - 13.99", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 940422, "fiftyTwoWeekLowChange": 3.7200003, "fiftyTwoWeekLowChangePercent": 0.3757576, "fiftyTwoWeekRange": "9.9 - 27.2", "fiftyTwoWeekHighChange": -13.580001, "fiftyTwoWeekHighChangePercent": -0.49926472, "fiftyTwoWeekChangePercent": -12.636304, "dividendDate": 1605225600, "earningsTimestamp": 1740657600, "earningsTimestampStart": 1746534600, "earningsTimestampEnd": 1747053000, "earningsCallTimestampStart": 1715169600, "earningsCallTimestampEnd": 1715169600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.07, "epsForward": -4.18, "epsCurrentYear": -4.04, "priceEpsCurrentYear": -3.371287, "fiftyDayAverageChange": -0.58650017, "fiftyDayAverageChangePercent": -0.04128393, "twoHundredDayAverageChange": -4.433776, "twoHundredDayAverageChangePercent": -0.24558719, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Miragen Therapeutics", "nameChangeDate": "2025-05-02", "averageAnalystRating": "1.5 - Buy", "cryptoTradeable": false, "displayName": "Viridian Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]